Goldman Sachs leads $150 million Aidoc round to scale clinical AI platform

Goldman Sachs Alternatives is backing AI that reaches far beyond office productivity. The firm led Aidoc’s $150 million Series E on April 29, a deal that pushed the clinical AI company’s total funding past $500 million and signaled where Goldman sees the next durable growth opportunities: regulated, high-stakes workflows where software has to earn trust from doctors, not just catch the market’s attention.

The round included General Catalyst, SoftBank Vision Fund 2 and NVentures. Goldman said the capital will accelerate Aidoc’s clinical foundation model and enterprise AI platform, while Aidoc said the money will help scale CARE, its clinical-grade foundation model, with a goal of supporting 90% of clinically relevant diseases within three years. Aidoc also said it is the clinical AI platform with the highest number of FDA-cleared solutions in its category.

For Goldman employees, the deal says a lot about where alternatives capital is going in 2026. This is not a back-office automation bet. It is a play on software that sits inside hospital decision-making, where speed, accuracy and adoption matter as much as growth. Aidoc says its AI tools cover 75% of patients in a health system, and its aiOS platform has surpassed 100 million analyzed patient cases, scale that helps explain why large, conservative buyers are willing to pay attention.

The company has also been building regulatory momentum. In 2026, Aidoc announced FDA breakthrough-device designation for a multi-triage solution, then later said it received FDA clearance for a comprehensive abdomen CT triage product powered by CARE. That workflow combined 11 newly cleared indications and three previously cleared indications into one system, a detail that matters in hospitals where every extra step can slow care.

Aidoc said the Series E came less than a year after a prior growth round led by General Catalyst and Square Peg, which, along with a $40 million revolving credit facility, brought total funding to $370 million at the time. The latest round also drew support from four major U.S. health systems, including Hartford HealthCare, Mercy, Sutter Health and WellSpan Health, underscoring that the buyer base is not just financial but operational.

The transaction fits a broader Goldman pattern this year, with Goldman Sachs Alternatives also active in healthcare and AI-related growth deals such as Sage and Fieldguide. For bankers and investors inside the firm, Aidoc is a clean example of where AI has moved from pitch decks to clinical authority, and why the most valuable deals may be the ones that improve safety, throughput and trust at the same time.